Methoden der Kostenbestimmung in der gesundheitsökonomischen Evaluation

Krauth, Christian

doi:10.1055/s-0029-1245680

Cited by 37 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nach der mengenmäßigen Erfassung des relevanten Ressourcenkonsums ist dessen monetäre Bewertung der dritte Schritt, um die assoziierten Kosten der Inanspruchnahme von Gesundheitsleistungen darzustellen. Die Höhe der monetären Bewertung einzelner Inanspruchnahmedaten hängt dabei von der gewählten Perspektive ab [ 3 ] . Aktuelle Standardisierungen von Bewertungssätzen bzw.…”

unclassified

Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation

et al. 2014

View full text Add to dashboard Cite

show abstract

unclassified

Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…We will include the costs of any type of health care and medicines (direct medical costs), travel expenses and also those for parking (direct non-medical costs), and the costs related to production losses (indirect costs) [86]. …”

Section: Methodsmentioning

confidence: 99%

Efficacy and cost-effectiveness of a web-based intervention with mobile phone support to treat depressive symptoms in adults with diabetes mellitus type 1 and type 2: design of a randomised controlled trial

et al. 2013

View full text Add to dashboard Cite

BackgroundA diagnosis of diabetes mellitus types 1 or 2 doubles the odds of a comorbid depressive disorder. The combined diseases have a wide range of adverse outcomes, such as a lower quality of life, poorer diabetes outcomes and increased healthcare utilisation. Diabetes patients with depression can be treated effectively with psychotherapy, but access to psychological care is limited. In this study we will examine the efficacy and cost-effectiveness of a newly developed web-based intervention (GET.ON Mood Enhancer Diabetes) for people with diabetes and comorbid depressive symptoms.Methods/DesignA two-arm randomised controlled trial will be conducted. Adults with diabetes (type 1 or type 2) with increased depression scores (> 22 on the German version of the Center for Epidemiological Studies Depression Scale (CES-D)) will be included. Eligible participants will be recruited through advertisement in diabetes patient journals and via a large-scale German health insurance company. The participants will be randomly assigned to either a 6-week minimally guided web-based self-help program or an online psychoeducation program on depression. The study will include 260 participants, which will enable us to detect a statistically significant difference with a group effect size of d = 0.35 at a power of 80% and a significance level of p = 0.05. The primary outcome measure will be the level of depression as assessed by the CES-D. The secondary outcome measures will be: diabetes-specific emotional distress, glycaemic control, self-management behaviour and the participants’ satisfaction with the intervention. Online self-assessments will be collected at baseline and after a 2 months period, with additional follow-up measurements 6 and 12 months after randomisation. The data will be analysed on an intention-to-treat basis and per protocol. In addition, we will conduct an economic evaluation from a societal perspective.DiscussionIf this intervention is shown to be cost-effective, it has considerable potential for implementing psychological care for large numbers of people with diabetes and comorbid depression in routine practice and improve health outcomes.Trial registrationGerman Clinical Trial Register (DRKS): DRKS00004748.

show abstract

“…travel expenses, investments in constructional alterations, legal fees and informal care -which means care provided by nonprofessional caregivers, in the majority family members). We used a micro-costing method to assess costs from a societal perspective [24].…”

Section: Cost Estimationmentioning

confidence: 99%

Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany

Osmanovic

Müschen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. Consequently, patients undergo a multidisciplinary treatment that often requires intensive use of medical resources. This study provides an estimate on the cost of illness depending on the clinical severity while also analysing the patients’ health-related quality of life.Methods Data from patients and caregivers was collected through a standardized questionnaire. Direct medical, direct non-medical and indirect costs were calculated using the latest German health economic guidelines. Patients were divided into five groups according to the King’s staging system. Health-related quality of life was assessed using EuroQoL Group EQ-5D-5LTM questionnaire. Influencing factors on both, total cost and quality of life, were examined.Results The mean annual total cost of illness was 78,256€ per patient while the lifetime cost per patient was estimated at 246,184€. The prevalence based total burden yearly therefore was 519,776,352€ in Germany. Nearly half of the costs were attributable to informal care. With increase of the clinical severity stage, costs rose and quality of life decreased. The score of the revised Amyotrophic Laterals Sclerosis Functional Rating Scale was identified as one major influencing factor on total costs, while subjective impairment in daily activities and classification into a care level influenced patients’ quality of life.Conclusion It is essential to understand the socioeconomic burden of a disease. These data can be used to improve patient care standards and quality of life while also serving as a basis for cost-benefit analyses during the approval process of new treatments.

show abstract

Methoden der Kostenbestimmung in der gesundheitsökonomischen Evaluation

Cited by 37 publications

References 17 publications

Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation

Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation

Efficacy and cost-effectiveness of a web-based intervention with mobile phone support to treat depressive symptoms in adults with diabetes mellitus type 1 and type 2: design of a randomised controlled trial

Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany

Contact Info

Product

Resources

About